Headlands Technologies LLC Has $111,000 Stake in uniQure N.V. (NASDAQ:QURE)

Headlands Technologies LLC lowered its position in uniQure N.V. (NASDAQ:QURE) by 43.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 10,496 shares of the biotechnology company’s stock after selling 7,954 shares during the period. Headlands Technologies LLC’s holdings in uniQure were worth $111,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Mraz Amerine & Associates Inc. acquired a new position in shares of uniQure during the 1st quarter worth $106,000. Wells Fargo & Company MN boosted its holdings in uniQure by 13.9% in the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock worth $217,000 after purchasing an additional 1,503 shares in the last quarter. XTX Topco Ltd acquired a new position in uniQure during the fourth quarter worth $287,000. Bellevue Group AG bought a new position in uniQure during the fourth quarter valued at about $397,000. Finally, Lighthouse Investment Partners LLC acquired a new stake in shares of uniQure in the fourth quarter worth about $397,000. Institutional investors own 78.83% of the company’s stock.

uniQure Stock Performance

NASDAQ QURE opened at $14.09 on Tuesday. The company’s fifty day moving average is $14.68 and its two-hundred day moving average is $13.63. uniQure N.V. has a 52-week low of $4.45 and a 52-week high of $19.18. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98. The firm has a market capitalization of $773.17 million, a price-to-earnings ratio of -3.59 and a beta of 0.11.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.20. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. The firm had revenue of $5.26 million for the quarter, compared to analyst estimates of $5.00 million. Equities research analysts forecast that uniQure N.V. will post -3.75 EPS for the current year.

Insiders Place Their Bets

In other uniQure news, Director David D. Meek sold 2,112 shares of uniQure stock in a transaction on Friday, June 20th. The shares were sold at an average price of $14.45, for a total transaction of $30,518.40. Following the sale, the director owned 34,190 shares in the company, valued at $494,045.50. The trade was a 5.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Robert Gut sold 3,336 shares of the stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $14.45, for a total transaction of $48,205.20. Following the completion of the transaction, the director directly owned 56,879 shares of the company’s stock, valued at $821,901.55. This trade represents a 5.54% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 22,144 shares of company stock valued at $322,426 in the last ninety days. 4.79% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on QURE. Chardan Capital lowered their price objective on uniQure from $38.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday, July 29th. Cantor Fitzgerald set a $47.00 target price on uniQure in a research report on Wednesday, July 30th. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, August 2nd. Guggenheim restated a “buy” rating and issued a $28.00 price objective on shares of uniQure in a research note on Monday, May 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of uniQure in a report on Thursday, May 29th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, uniQure presently has an average rating of “Moderate Buy” and a consensus target price of $36.55.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.